All In Biotech

Drug Trial Radar · NCT02683213

Efficacy of Fluoxetine - a Trial in Stroke

Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke

Last checked: Nov 20, 2026Latest source record: Sep 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,500

Actual

Start

Oct 20, 2014

Primary completion

Jun 2020

Study completion Jun 2020

Sponsor

Lead sponsor
Karolinska InstitutetAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Research Council; Swedish Heart Lung Foundation; Stroke-Riksförbundet; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; Hjärnfonden (The Swedish Brain foundation); The Swedish Medical Association
First posted
Feb 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate whether routine administration of fluoxetine 20mg once daily in the 6 months initiated during the acute stroke improves the patient's functional outcome. EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind placebo controlled trial with broad entry criteria and follow up at 6 and 12 months. EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October 2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and the primary outcome is due to report on May 2020.

Conditions

  • Stroke

Interventions

  • FluoxetineDrug

    Fluoxetine 20mg once daily for 6 months.

  • PlaceboDrug

    Matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional status, measured with the modified Rankin scale.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Karolinska Institutet

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.